Today's story
Novo Nordisk Halts Two Ziltivekimab Heart Trials
Novo Nordisk has halted two more ziltivekimab trials in heart failure after a data monitor found limited likelihood of success, adding to the earlier ZEUS setback and leaving only the post‑myocardial infarction ARTEMIS study as the remaining program. A separate post‑MI study is continuing with results expected in early 2027, underscoring ongoing challenges for inflammation‑targeting cardiovascular therapies.
Health · 8 sources · Sep 9, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About heart failure
Heart failure (HF), also known as congestive heart failure (CHF), is a syndrome caused by an impairment in the heart's ability to fill with and pump blood.
Everything about heart failure →